Sign In
Buy VANI
$1.28
-0.0200 (-1.54%)
At Close: Jun 03, 2026
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Wednesday, 13'th May 2026
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivale
Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases $1,999,999.26 in Stock
04:22am, Sunday, 19'th Apr 2026
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The stock was purc
Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Up 65.0% in March
02:20am, Wednesday, 15'th Apr 2026
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 532,131 s
Critical Survey: Verrica Pharmaceuticals (NASDAQ:VRCA) vs. Vivani Medical (NASDAQ:VANI)
01:03am, Sunday, 05'th Apr 2026
Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast th
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 03'rd Apr 2026
Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:16pm, Thursday, 26'th Mar 2026
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under
Vivani Medical (VANI) Projected to Post Quarterly Earnings on Monday
02:32am, Monday, 23'rd Mar 2026
Vivani Medical (NASDAQ: VANI - Get Free Report) is projected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Vivani Medical to post earnings of ($0.10) per s
Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4%
01:55am, Monday, 16'th Mar 2026
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 290,597 shares,
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
01:58am, Sunday, 15'th Mar 2026
VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two comp
First Look: WBD waiver; Ackman's Meta bet; Ford-China JV
07:39am, Tuesday, 17'th Feb 2026
Stock News WBD reopens rival talks under Netflix waiver: Warner Bros. Discovery (WBD) received a seven-day waiver from Netflix (NFLX) to resume talks with Param
Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Update
01:58am, Friday, 13'th Feb 2026
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 401,264 s
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
07:30am, Thursday, 29'th Jan 2026
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial
Vivani Medical, Inc. Announces Closing of Common Stock Offering
04:05pm, Tuesday, 27'th Jan 2026
ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
11:36pm, Sunday, 25'th Jan 2026
ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-
Gregg Williams Purchases 1,737,765 Shares of Vivani Medical (NASDAQ:VANI) Stock
04:42am, Thursday, 18'th Dec 2025
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) Director Gregg Williams acquired 1,737,765 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were bought at
